替西木单抗联合消融治疗晚期肝细胞癌患者
32例晚期肝细胞癌患者接受替西木单抗(3.5或10mg/kg静脉注射,每4周一次共6次,后每3个月一次)联合消融治疗,未出现剂量限制性毒性,最常见毒性为瘙痒;可评估的19例中5例(26.3%,95%CI 9.1-51.2%)获确认的部分缓解,中位总生存期12.3个月。
要点
- 替西木单抗联合消融未出现剂量限制性毒性,最常见毒性为瘙痒。
- 可评估19例中5例(26.3%,95%CI 9.1-51.2%)获确认的部分缓解。
- 中位总生存期12.3个月(95%CI 9.3-15.4个月),中位至肿瘤进展时间7.4个月(95%CI 4.7-19.4个月)。
核心结论
- 替西木单抗联合肿瘤消融是晚期肝细胞癌患者的潜在新治疗,可导致瘤内CD8+ T细胞积聚,观察到阳性临床活性,并可能有替代性的HCV病毒载量降低。
研究设计与样本
- 研究纳入32例肝细胞癌患者,男28例、女4例,中位年龄62岁(范围36-76岁)。
- 患者接受两个剂量水平(3.5和10mg/kg静脉注射)的替西木单抗,每4周一次共6次,随后每3个月输注一次直至满足停药标准。
- 第36天患者接受次全射频消融或化学消融,每8周通过增强CT或MRI进行分期。
主要发现
- 未遇到剂量限制性毒性,最常见的毒性为瘙痒。
- 可评估的19例患者中,5例(26.3%;95%CI:9.1-51.2%)达到确认的部分缓解。
- 14例可定量HCV的患者中12例病毒载量显著下降。
- 6周肿瘤活检显示,仅在临床获益的患者中CD8+ T细胞明显增加。
- 该难治性肝细胞癌人群的6个月和12个月无肿瘤进展生存概率分别为57.1%和33.1%,中位至肿瘤进展时间为7.4个月(95%CI 4.7至19.4个月),中位总生存期为12.3个月(95%CI 9.3至15.4个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tremelimumab is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes. Ablative therapies induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced hepatocellular carcinoma (HCC). This study aimed to demonstrate whether tremelimumab could be combined safely and feasibly with ablation. METHODS: Thirty-two patients with HCC were enrolled: male:female: 28:4; median age: 62 (range 36-76). Patients were given tremelimumab at two dose levels (3.5 and 10mg/kg i.v.) every 4weeks for 6 doses, followed by 3-monthly infusions until off-treatment criteria were met. On day 36, patients underwent subtotal radiofrequency ablation or chemoablation. Staging was performed by contrast-enhanced CT or MRI scan every 8weeks. RESULTS: No dose-limiting toxicities were encountered. The most common toxicity was pruritus. Of the 19 evaluable patients, five (26.3%; 95% CI: 9.1-51.2%) achieved a confirmed partial response. Twelve of 14 patients with quantifiable HCV experienced a marked reduction in viral load. Six-week tumor biopsies showed a clear increase in CD8+ T cells in patients showing a clinical benefit only. Six and 12-month probabilities of tumor progression free survival for this refractory HCC population were 57.1% and 33.1% respectively, with median time to tumor progression of 7.4months (95% CI 4.7 to 19.4months). Median overall survival was 12.3months (95% CI 9.3 to 15.4months). CONCLUSIONS: Tremelimumab in combination with tumor ablation is a potential new treatment for patients with advanced HCC, and leads to the accumulation of intratumoral CD8+ T cells. Positive clinical activity was seen, with a possible surrogate reduction in HCV viral load. LAY SUMMARY: Studies have shown that the killing of tumors by direct methods (known as ablation) can result in the immune system being activated or switched on. The immune system could potentially also recognize and kill the cancer that is left behind. There are new drugs available known as immune checkpoint inhibitors which could enhance this effect. Here, we test one of these drugs (tremelimumab) together with ablation. CLINICAL TRIAL NUMBER: ClinicalTrials.gov: NCT01853618.
引用
- Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2016. PMID: 27816492. doi:10.1016/j.jhep.2016.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。